Allergan PLC. Company Profile (NYSE:AGN)

About Allergan PLC. (NYSE:AGN)

Allergan PLC. logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:AGN
  • CUSIP: 01849010
  • Web:
  • Market Cap: $82.77778 billion
  • Outstanding Shares: 335,867,000
Average Prices:
  • 50 Day Moving Avg: $230.38
  • 200 Day Moving Avg: $227.81
  • 52 Week Range: $184.50 - $261.27
  • Trailing P/E Ratio: 7.76
  • Foreward P/E Ratio: 13.76
  • P/E Growth: 1.24
Sales & Book Value:
  • Annual Revenue: $14.74 billion
  • Price / Sales: 5.67
  • Book Value: $209.35 per share
  • Price / Book: 1.19
  • Annual Dividend: $2.80
  • Dividend Yield: 1.1%
  • EBIDTA: $5.8 billion
  • Net Margins: 82.42%
  • Return on Equity: 7.29%
  • Return on Assets: 4.08%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 1.32%
  • Quick Ratio: 1.23%
  • Average Volume: 2.30 million shs.
  • Beta: 1.16
  • Short Ratio: 2.45

Frequently Asked Questions for Allergan PLC. (NYSE:AGN)

What is Allergan PLC.'s stock symbol?

Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?

Allergan PLC. declared a quarterly dividend on Friday, May 5th. Stockholders of record on Thursday, May 18th will be given a dividend of $0.70 per share on Thursday, June 15th. This represents a $2.80 annualized dividend and a dividend yield of 1.12%. The ex-dividend date is Tuesday, May 16th. View Allergan PLC.'s Dividend History.

How were Allergan PLC.'s earnings last quarter?

Allergan PLC. (NYSE:AGN) posted its quarterly earnings results on Tuesday, May, 9th. The company reported $3.35 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.32 by $0.03. The business earned $3.57 billion during the quarter, compared to analyst estimates of $3.53 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The business's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.04 EPS. View Allergan PLC.'s Earnings History.

When will Allergan PLC. make its next earnings announcement?

Allergan PLC. is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Allergan PLC..

What guidance has Allergan PLC. issued on next quarter's earnings?

Allergan PLC. issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of $15.85-16.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.01.

Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?

17 brokerages have issued 12 month target prices for Allergan PLC.'s shares. Their forecasts range from $205.00 to $400.00. On average, they expect Allergan PLC.'s stock price to reach $273.00 in the next year. View Analyst Ratings for Allergan PLC..

What are analysts saying about Allergan PLC. stock?

Here are some recent quotes from research analysts about Allergan PLC. stock:

  • 1. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
  • 2. According to Zacks Investment Research, "Allergan is reshaping its portfolio through acquisitions/divestitures. Allergan has been pretty active on the acquisition front and made six new product acquisitions in the third quarter. With the Allergan, Inc. acquisition, the company finds itself among the top 10 pharmas worldwide based on sales. Moreover, with the closing of the Teva deal, the company’s restructured and simplified business is encouraging. As a result, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent significant opportunity. Also, Allergan’s shares outperformed the generic industry in past six months. However, while we remain optimistic about the company’s growth prospects, the company is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us." (1/3/2017)

Who are some of Allergan PLC.'s key competitors?

Who owns Allergan PLC. stock?

Allergan PLC.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.00%), State Street Corp (4.74%), Janus Capital Management LLC (1.13%), Bank of New York Mellon Corp (1.09%), Veritas Asset Management LLP (0.00%) and TIAA CREF Investment Management LLC (0.00%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..

Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?

Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Baupost Group LLC MA, Paulson & CO. Inc., Macquarie Group Ltd., TCW Group Inc., TIAA CREF Investment Management LLC and Saba Capital Management L.P.. Company insiders that have sold Allergan PLC. stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..

Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?

Allergan PLC.'s stock was purchased by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Iridian Asset Management LLC CT, Renaissance Technologies LLC, Blue Ridge Capital L.L.C., First Manhattan Co., Canyon Capital Advisors LLC, Schroder Investment Management Group and Swiss National Bank. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..

How do I buy Allergan PLC. stock?

Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan PLC.'s stock price today?

One share of Allergan PLC. stock can currently be purchased for approximately $248.91.

MarketBeat Community Rating for Allergan PLC. (NYSE AGN)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  801 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  1,130
MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $273.00 (9.68% upside)

Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017Cantor FitzgeraldInitiated CoverageNeutral -> Neutral$231.00LowView Rating Details
6/12/2017Royal Bank Of CanadaSet Price TargetBuy$284.00LowView Rating Details
6/9/2017MizuhoLower Price TargetBuy -> Buy$275.00 -> $267.00MediumView Rating Details
6/8/2017Cowen and CompanySet Price TargetBuy$400.00MediumView Rating Details
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
5/10/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$262.00HighView Rating Details
4/24/2017Citigroup Inc.Boost Price TargetBuy$261.00LowView Rating Details
3/28/2017Deutsche Bank AGBoost Price TargetBuy$262.00 -> $265.00LowView Rating Details
2/22/2017Piper Jaffray CompaniesSet Price TargetHold$205.00N/AView Rating Details
2/14/2017Credit Suisse GroupReiterated RatingBuy$274.00N/AView Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00N/AView Rating Details
12/23/2016Bank of America CorporationReiterated RatingBuy$280.00N/AView Rating Details
12/6/2016ArgusReiterated RatingBuy$340.00 -> $260.00N/AView Rating Details
12/5/2016J P Morgan Chase & CoSet Price TargetBuy$300.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Morgan StanleyLower Price TargetOverweight$300.00 -> $274.00N/AView Rating Details
10/31/2016Barclays PLCReiterated RatingEqual Weight$250.00N/AView Rating Details
6/10/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 6/27/2015 forward)


Earnings History for Allergan PLC. (NYSE:AGN)
Earnings by Quarter for Allergan PLC. (NYSE:AGN)
Earnings History by Quarter for Allergan PLC. (NYSE AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan PLC. (NYSE:AGN)
2017 EPS Consensus Estimate: $16.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$3.85$4.07$3.96
Q3 20172$4.09$4.16$4.13
Q4 20172$4.35$4.67$4.51
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan PLC. (NYSE:AGN)
Most Recent Dividend:6/15/2017
Annual Dividend:$2.80
Dividend Yield:1.12%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:9.63% (Trailing 12 Months of Earnings)
17.39% (Based on This Year's Estimates)
15.48% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Allergan PLC. (NYSE:AGN)

Dividend History by Quarter for Allergan PLC. (NYSE AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE:AGN)
Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 84.63%
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE:AGN)
DateHeadline logoAllergan PLC. (AGN) Lifted to Buy at BidaskClub - June 24 at 9:06 PM logoStock Traders Purchase High Volume of Allergan PLC. Put Options (AGN) - June 23 at 12:37 PM logoInvestors Purchase Large Volume of Allergan PLC. Call Options (AGN) - June 22 at 12:32 PM logoMissouri sues opioid manufacturers, joining two other U.S. states - June 21 at 4:10 PM logoTodd Hagopian's Top 2 Mental Health Biotech Stocks - June 21 at 4:10 PM logoAllergan PLC. (AGN) Receives Consensus Recommendation of "Buy" from Brokerages - June 21 at 12:38 AM logoAllergan Is Putting the Bull Back in Charge - June 19 at 3:27 PM logoAllergan PLC. (AGN) Raised to "Hold" at BidaskClub - June 17 at 7:52 PM logoAllergan PLC. (AGN) Expected to Announce Quarterly Sales of $3.96 Billion - June 16 at 1:56 PM logoAllergan PLC. (AGN) Earns Neutral Rating from Analysts at Cantor Fitzgerald - June 16 at 10:06 AM logoAllergan Plc breached its 50 day moving average in a Bullish Manner : AGN-US : June 15, 2017 - June 15 at 4:58 PM logoAllergan CEO on the battle over drug pricing - June 15 at 4:58 PM logo5 Things Allergan's Management Just Said That You Need to Know - June 15 at 4:58 PM logo5 Things Allergan's Management Just Said That You Need to Know - June 15 at 3:44 PM logoExecutive order on drug pricing could have positive outcome: Allergan CEO - June 15 at 3:44 PM logo$4.00 Earnings Per Share Expected for Allergan PLC. (AGN) This Quarter - June 14 at 6:22 PM logoAllergan PLC. (AGN) Given a $284.00 Price Target by Royal Bank Of Canada Analysts - June 13 at 5:56 PM logoOpioid Stocks Feel the Pressure of FDA Measures - June 12 at 4:28 PM logoAllergan plc (AGN) PT Set at $400.00 by Cowen and Company - June 11 at 9:02 AM logoAllergan plc (AGN) Price Target Lowered to $267.00 at Mizuho - June 10 at 12:32 PM logoAllergan to buy medical device company and breast surgery funnel ... - MarketWatch - June 8 at 1:00 AM logoAmgen (AMGN) & Allergan (AGN) Reports FDA Advisory Committee Meeting To Review ABP 215 (Biosimilar ... - - June 7 at 3:30 PM logoAlkermes Gets FDA Nod for Two Month Dose of Aristada - June 7 at 3:30 PM logoGoldman Reveals Top Stocks Owned By Hedge Funds This Year - June 5 at 6:30 PM logoBullish Two Hundred Day Moving Average Cross - AGN - June 2 at 1:32 AM logoPRESS DIGEST - Wall Street Journal - June 1 - June 1 at 1:25 AM logoJohnson and Johnson, other drug companies accused of viol... - May 31 at 3:23 PM logoLeon Cooperman Bets On These 19 Stocks - May 31 at 3:23 PM logoOhio Going After Drug Makers for Fueling Opioid Crisis - May 31 at 3:23 PM logoOhio attorney general sues 5 drugmakers over opiate crisis - May 31 at 3:23 PM logoAllergan to Present Data from its Anti-Infectives Portfolio at ASM Microbe 2017 in New Orleans - May 31 at 11:09 AM logoPaulson & Co. Hedge Fund Cuts Back on Health Care in Q1 - May 30 at 3:33 PM logoKey Moves by Billionaire David Tepper's Appaloosa Mgmt in Q1: 13F Filings - May 30 at 3:33 PM logoTrumpCare isn't moving health care stocks because it won't pass: NYSE trader - May 27 at 3:27 PM logoAllergan plc (AGN) Receives Outperform Rating from Sanford C. Bernstein - May 27 at 1:24 PM logoAllergan plc (AGN) Given Average Recommendation of "Buy" by Brokerages - May 27 at 12:46 AM logoAllergan plc Sees Unusually High Options Volume (AGN) - May 26 at 1:00 PM logoAllergan Announces Early Tender Results and Upsizing of Tender Offers by Certain Subsidiaries - May 24 at 3:24 PM logoShark Bites: Focus on the 'Little Picture' - May 24 at 3:24 PM logoTracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2017 Update - May 24 at 6:55 AM logoAllergan Announces Pricing of Public Offering of Senior Notes to Refinance Existing Debt - May 24 at 6:55 AM logoKristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE™ (Oxymetazoline HCL) Cream, 1% - May 24 at 6:55 AM logoAllergan Funding SCS -- Moody's assigns Baa3 to Allergan's euro notes; stable outlook - May 23 at 3:27 PM logoHas Allergan's Pullback Run Its Course? - May 23 at 3:27 PM logoAllergan launches offering of senior unsecured notes to rollover existing debt - May 23 at 7:29 AM logoAllergan Announces Commencement of Proposed Public Offering of Senior Notes to Refinance Existing Debt - May 23 at 6:43 AM logoThese Big Drug Stocks May Cure the Trump Blues - May 23 at 6:43 AM logoNesli Basgoz Sells 1,889 Shares of Allergan plc (AGN) Stock - May 22 at 7:46 PM logoValeant Pharmaceuticals: Intrigued…Really? - May 19 at 3:24 PM logoAllergan's Irritable Bowel Drug Viberzi Approved in Canada - May 17 at 12:37 PM



Allergan PLC. (AGN) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by Staff